Aura Biosciences AURA 深 沪
等待开盘 08-20 09:30:00 美东时间
7.79
-0.370
-4.53%
华盛通- 最 高8.366
- 今 开8.28
- 成交量 114.45万股
- 最 低 7.695
- 昨 收 8.16
- 总市值 8.08亿
- 52周最高 9.535
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 4.73
- 委 比 -91.64%
- 总股本 1.04亿
- 历史最高 26.16
- 量 比 0.80
- 振 幅 8.22%
- 历史最低 4.345
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio reported progress on its Phase 3 ELAINE-3 trial for lasofoxifene in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with enrollment on track to complete by Q4 2026 and topline data expected in H2 2027. The company highlighted lasofoxifene's potential as a transformative treatment and discussed its favorable safety and efficacy profile from earlier studies. Financially, LeonaBio ended Q2 2026 with $51.1 million in cash ...
08-14 20:05
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Aura Biosciences (NASDAQ:AURA) with a Buy and lowers the price target from $24 to $18.
08-12 00:11
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 29.73 percent. This is a 2.13 percent decrease over losses of $(0.47) per share from the same period last year.
08-11 19:22
Aura Biosciences Expands Authorized Shares and Incentive Plan
An announcement from Aura Biosciences Inc ( ($AURA) ) is now available. On Augu...
08-06 05:23
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday. Shares of Deckers Outdoor Corp (NYSE:DECK) fell sharply in pre-market trading after the company reported first-quarter financial results. Deckers Outdoor reported quarterly earnings of 94 cents per...
07-24 20:04
Aura Biosciences strengthens board with new independent director
Aura Biosciences Inc ( ($AURA) ) just unveiled an update. On July 3, 2026, Aura...
07-08 19:48
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender, a biotech leader with experience in advancing therapies and commercialization, joins as the company prepares for potential regulatory approval of bel-sar for early choroidal melanoma. Aura aims to develop precision therapies preserving organ function, with bel-sar in late-stage development. Bender previously led Day One Biopharmaceuticals through its $2.5 b...
07-08 11:01
Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027
Topline data for the 15-month primary endpoint are anticipated in the second half of 2027."Completing enrollment in our Phase 3 CoMpass trial marks a significant milestone for Aura as we advance bel-sar toward a
06-01 20:14
